Spravato Approved for Treatment-Resistant Depression

Spravato Approved for Treatment-Resistant Depression

February 25, 2025 Spravato, the esketamine nasal spray approved in 2019 for use alongside oral antidepressants for treatment-resistant depression, has been approved by the U.S. Food and Drug Administration (FDA) as a standalone monotherapy with no oral medication required. Esketamine is a form of the dissociative agent ketamine, commonly used as an anesthetic; it works by targeting the neurotransmitter glutamate. According to a randomized, doubl…